The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
 
Alexandra Thomas
Stock and Other Ownership Interests - Bristol-Myers Squibb; Doximity; Gilead Sciences; Johnson & Johnson (I); Pfizer
Consulting or Advisory Role - AstraZeneca
Research Funding - Merck (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Up-to-Date Royalties (I)
 
Denise M. Wolf
No Relationships to Disclose
 
Ronald Balassanian
Stock and Other Ownership Interests - Cerus
Consulting or Advisory Role - Genentech
 
Yunn-Yi Chen
No Relationships to Disclose
 
Julia Ye
No Relationships to Disclose
 
Poonam Vohra
No Relationships to Disclose
 
Evin H. Gulbahce
No Relationships to Disclose
 
Alexander D. Borowsky
Leadership - Histolix
Stock and Other Ownership Interests - Histolix
Consulting or Advisory Role - Tempus
Research Funding - Danaher (Inst)
 
Lamorna Brown Swigart
No Relationships to Disclose
 
Gillian L. Hirst
No Relationships to Disclose
 
Sara Venters
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Rebecca Arielle Shatsky
Consulting or Advisory Role - AstraZeneca; Endeavor BioMedicines; Lilly; Novartis; Stemline Therapeutics; TEMPUS
Speakers' Bureau - Gilead Sciences
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Genentech (Inst); OBI Pharma (Inst); Phoenix Molecular Designs (Inst); QuantumLeap Health (Inst)
 
Ralph D'Agostino
Consulting or Advisory Role - biogen; Bluebird Bio; Bristol-Myers Squibb/Celgene; Exelixis; Jazz Pharmaceuticals; Merck; Secura Bio
 
Rita A. Mukhtar
Patents, Royalties, Other Intellectual Property - Patent on the use of fibrin and silver microparticles to promote wound healing. (I)
 
Sarah Hatcher
No Relationships to Disclose
 
Christina Yau
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No. 63/314,065 (Inst); U.S. Provisional Application No. 63/341,579 (Inst); US Application No. 18/174,191 (Inst)
 
Angela DeMichele
Consulting or Advisory Role - Pfizer (I)
Research Funding - Genentech (Inst); Inivata/NeoGenomics (Inst); Novartis (Inst); Pfizer (Inst)
 
Laura van 't Veer
Employment - Agendia
Stock and Other Ownership Interests - Agendia; Exai Bio
 
Laura Esserman
Consulting or Advisory Role - Blue Cross Blue Shield Association
Research Funding - Moderna Therapeutics (Inst)
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative